summari
human
respiratori
tract
entri
point
known
virus
collect
contribut
million
annual
death
worldwid
consequ
world
health
organ
design
respiratori
viral
infect
prioriti
vaccin
develop
despit
enorm
advanc
understand
attribut
protect
mucos
antivir
immun
respons
current
vaccin
continu
fail
effect
gener
longliv
protect
tcell
immun
date
major
licens
human
vaccin
afford
protect
infecti
pathogen
gener
specif
immunoglobulin
respons
recent
year
select
manipul
specif
costimulatori
pathway
critic
regul
cellmedi
immun
respons
gener
increas
interest
impress
result
anim
model
shown
tumor
necrosi
factor
receptor
tnfr
famili
member
bind
partner
key
costimulatori
molecul
involv
gener
protect
tcell
respons
mucos
surfac
lung
review
highlight
new
find
particular
emphasi
potenti
immunolog
adjuv
enhanc
poxvirusbas
tcell
vaccin
keyword
cell
vaccin
influenza
poxvirus
lung
mucos
surfac
respiratori
tract
provid
optim
condit
effici
gaseou
exchang
unfortun
ideal
portal
entri
innocu
environment
antigen
human
pathogen
consequ
bodi
respiratori
mucos
surfac
contain
complex
array
immun
regulatori
mechan
ensur
least
healthi
individu
quiescent
noninflammatori
environ
maintain
optim
tissu
function
howev
pathogen
establish
infect
regulatori
mechan
fail
rapid
cascad
event
lead
product
inflammatori
cytokin
recruit
immun
cell
attempt
erad
ensu
pathogen
antigen
stimuli
minim
impact
physiolog
function
tissu
howev
ideal
conclus
often
occur
mani
human
articl
part
seri
review
cover
tnf
receptor
famili
member
appear
volum
immunolog
review
pathogen
evolv
virul
immun
modulatori
mechan
circumv
disrupt
mucos
immun
respons
result
tissu
patholog
clinic
diseas
possibl
longterm
sequela
help
minim
detriment
impact
respiratori
infect
vaccin
develop
mani
preval
respiratori
pathogen
includ
bordatella
pertussi
whoop
cough
corynebacterium
diphtheria
diptheria
haemophilu
influenza
type
b
hib
streptococcu
pneumonia
pneumococc
pneumonia
otiti
media
success
reduc
infant
mortal
burden
infecti
diseas
worldwid
yet
despit
continu
success
widespread
use
respiratori
pathogen
vaccin
mycobacterium
tuberculosi
tb
multitud
respiratori
viral
infect
continu
caus
signific
morbid
result
million
futil
death
year
world
health
organ
global
burden
diseas
influenza
viru
alon
caus
season
epidem
affect
global
popul
recent
estim
suggest
season
influenza
viral
infect
respons
death
annual
increas
pandem
caus
emerg
novel
reassort
viral
strain
global
burden
diseas
furthermor
increas
number
death
attribut
human
transmiss
highli
pathogen
avian
influenza
strain
elev
influenza
viru
associ
morbid
mortal
addit
influenza
viru
parainfluenza
viru
respiratori
syncyti
viru
rsv
metapneumonia
viru
sever
acut
respiratori
syndrom
coronaviru
sarscov
rhinoviru
measl
adenoviru
endem
within
human
popul
establish
acut
respiratori
tract
infect
except
exist
approach
fail
develop
effect
vaccin
viral
pathogen
omin
public
health
impact
respiratori
infect
like
increas
near
futur
due
age
global
popul
increas
antibiot
resist
case
tb
pneumococcu
alter
social
attitud
toward
vaccin
moreov
continu
emerg
novel
respiratori
virus
antigen
recombin
event
zoonosi
influenza
viru
strain
highli
pathogen
avian
influenza
virus
sar
coronaviru
human
case
monkeypox
taken
togeth
continu
concern
bioterror
anthrax
smallpox
add
urgent
need
better
understand
pathogenesi
respiratori
virus
mechan
protect
review
discuss
rational
develop
tcell
vaccin
exist
emerg
human
respiratori
virus
review
current
understand
antigenspecif
tcell
induct
memori
format
context
respiratori
viral
infect
argument
made
appli
knowledg
critic
futur
success
tcell
vaccin
examin
attenu
poxvirus
develop
past
three
decad
candid
vaccin
varieti
mucos
pathogen
discuss
futur
effort
focu
understand
molecular
term
live
nonattenu
vaccin
result
better
tcell
immun
final
section
discuss
member
tumor
necrosi
factor
receptor
tnfr
tnf
superfamili
specif
bind
partner
rapidli
emerg
key
player
develop
protect
tcell
memori
lung
becom
evid
alreadi
mean
develop
poxvirusbas
vaccin
deliveri
system
establish
far
better
protect
tcell
immun
lung
anyth
current
avail
today
licens
vaccin
work
promot
robust
longliv
immunoglobulin
respons
prevent
initi
pathogen
infect
ensu
replic
result
pathogen
clearanc
onset
clinic
symptom
appar
straightforward
approach
safe
gener
neutral
immunoglobulin
via
inject
kill
subunit
highli
attenu
agent
result
mani
success
vaccin
confer
lifelong
protect
immun
howev
context
highli
pathogen
rapidli
mutat
virus
target
mucos
surfac
respiratori
tract
approach
proven
far
less
success
limit
gener
sole
immunoglobulinmedi
protect
highlight
necess
annual
develop
season
influenza
vaccin
protect
mechan
current
subunit
inactiv
influenza
vaccin
gener
neutral
immunoglobulin
hemagglutinin
ha
neuraminidas
na
two
integr
membran
viral
protein
essenti
infect
although
immunoglobulin
surfac
protein
longliv
function
relev
diminish
rapidli
due
antigen
drift
ha
na
surfac
glycoprotein
continu
antigen
drift
evolut
also
explain
part
difficulti
develop
effect
vaccin
intracellular
pathogen
human
immunodefici
viru
hiv
malaria
pathogen
continu
mutat
case
hiv
alter
case
plasmodium
parasit
key
surfac
antigen
result
immunolog
escap
inducedspecif
immunoglobulin
respons
continu
dilemma
led
gener
accept
develop
effect
vaccin
type
intracellular
pathogen
combin
immunoglobulin
longlast
memori
tcell
respons
must
gener
approach
ad
benefit
produc
crossprotect
immun
mediat
cell
recogn
conserv
intern
compon
specif
pathogen
therefor
confer
heterosubtyp
immun
would
ideal
strategi
context
viru
rapidli
mutat
extern
antigen
maintain
conserv
intern
antigen
strictli
speak
cell
afford
protect
infect
per
se
mediat
faster
viral
clearanc
provid
substanti
degre
protect
challeng
lethal
dose
viru
toward
end
scientif
commun
focus
enorm
effort
develop
prophylact
therapeut
vaccin
promot
tcell
respons
assumpt
strategi
enhanc
immunolog
protect
provid
addit
support
exist
antivir
immunoglobulin
respons
date
howev
develop
effect
tcell
vaccin
mani
respiratori
virus
remain
elus
past
year
immunologist
provid
vaccinologist
valuabl
inform
regulatori
mechan
govern
effici
gener
tcell
respons
lung
also
differ
memori
tcell
subset
maintain
time
current
challeng
appli
knowledg
endeavor
develop
safe
effect
tcell
vaccin
virus
oblig
intracellular
parasit
upon
gain
entri
hostcel
hijack
host
transcript
protein
synthesi
machineri
gener
progeni
virion
initi
next
cycl
infect
consequ
respiratori
epithelium
contain
array
viru
detect
system
tolllik
receptor
tlr
nodlik
receptor
nlr
cytosol
rna
helicas
famili
member
retino
acidinduc
gene
rig
melanoma
differenti
associ
gene
act
concert
rapidli
detect
presenc
invad
viru
upon
viral
recognit
complex
interplay
distinct
detect
system
result
activ
array
transcript
factor
culmin
product
antivir
cytokin
inflammatori
mediat
addit
establish
local
inflammatori
environ
recruit
innat
effector
cell
initi
antivir
inflammatori
program
import
activ
differenti
lungresid
antigenpres
cell
apc
name
dendrit
cell
dc
macrophag
much
current
understand
tcell
immun
stem
studi
small
rodent
influenza
parainfluenza
infect
model
model
shown
crucial
role
cell
play
control
viral
titer
primari
infect
gener
protect
subsequ
infect
fig
depict
event
occur
lung
parenchyma
airway
drain
lymph
node
ln
initi
stage
subleth
intranas
infect
influenza
viru
within
coupl
day
infect
viral
titer
lung
increas
rapidli
culmin
acut
weight
loss
cachexia
subsequ
antigenload
infect
respiratori
dc
migrat
mediastin
ln
mln
within
h
reach
maxim
number
h
postinfect
intravit
ln
microscopi
studi
suggest
antigenbear
dc
migrat
local
vicin
highendotheli
venul
hev
hev
local
event
facilit
dc
interact
naiv
antigenspecif
cell
enter
ln
peripher
circul
rel
rare
antigenspecif
cell
subsequ
select
tcell
receptor
tcr
major
histocompat
complex
class
mhc
engag
undergo
round
clonal
expans
result
larg
popul
antigenspecif
effector
cell
observ
peak
primari
respons
expans
phase
cell
simultan
differenti
function
distinct
effector
popul
base
cytokin
secret
profil
includ
cytotox
cell
popul
correspond
better
describ
thelper
cell
popul
homeostat
tcell
clone
frequenc
specif
antigen
peptid
abund
present
kinet
collect
influenc
develop
rel
frequenc
domin
subdomin
tcell
popul
earli
day
four
five
postinfect
cell
present
lung
tissu
exhibit
sever
effector
function
includ
abil
secret
antivir
cytokin
interferonc
ifnc
tumor
necrosi
factor
tnfa
initi
cell
kill
virusinfect
epitheli
cell
fa
trail
perforinmedi
lysi
migrat
cell
lung
tissu
airway
appear
depend
antigen
although
infiltr
cell
must
acquir
suffici
level
activ
downregul
ln
home
receptor
acquir
lunghom
chemokin
receptor
follow
arriv
lung
protect
virusspecif
tcell
respons
requir
addit
antigendepend
interact
respiratori
dc
respiratori
dc
critic
contribut
sustain
surviv
virusspecif
effector
cell
transpresent
recent
data
also
suggest
mediat
migrat
effector
cell
lung
airway
togeth
data
support
twohit
model
promot
effect
tcell
respons
first
hit
lymph
node
prime
tcell
prolifer
migrat
site
infect
second
hit
provid
surviv
signal
effector
cell
influx
virusspecif
cell
respiratori
tract
coincid
decreas
viral
titer
recoveri
bodi
mass
ultim
viral
clearanc
day
eight
postinfect
viral
clearanc
major
virusspecif
effector
cell
die
apoptosi
small
popul
surviv
effector
cell
persist
seed
longliv
memori
pool
cardin
featur
memori
cell
abil
mediat
faster
stronger
effect
respons
secondari
viru
challeng
naiv
cell
case
cell
increas
number
higher
activ
statu
rapid
induct
effector
function
alter
home
pattern
contribut
enhanc
recal
respons
recent
year
accumul
data
highlight
memori
cell
extrem
heterogen
term
phenotyp
function
anatom
distribut
two
major
subtyp
memori
cell
defin
base
express
also
known
lselectin
home
receptor
leukocyt
enter
sec
ondari
lymphoid
tissu
via
hev
chemokin
receptor
support
traffick
secondari
lymphoid
tissu
fig
central
memori
cell
cm
hi
hi
cell
tend
local
secondari
lymphoid
tissu
wherea
effector
memori
cell
em
lo
lo
cell
local
traffic
peripher
tissu
lung
consider
interest
focus
elucid
function
differ
memori
tcell
subset
capac
confer
protect
secondari
infect
secondari
encount
antigen
em
cell
stimul
respiratori
dc
without
requir
divis
demonstr
rapid
cytokin
product
lytic
activ
contrast
rest
cm
cell
resid
ln
requir
migratori
dc
reactiv
result
de
novo
prolifer
new
wave
secondari
effector
cell
migrat
lung
parenchyma
airway
base
observ
propos
em
cell
particip
directli
initi
protect
memori
respons
rapidli
produc
effector
molecul
perforin
granzym
antivir
cytokin
site
antigen
encount
cm
cell
contribut
mainten
amplif
overal
secondari
tcell
respons
therefor
specif
subset
memori
cell
gener
vaccin
may
critic
determin
ultim
effect
vaccin
inducedimmun
protect
natur
respiratori
viral
infect
sever
key
issu
must
taken
account
develop
effect
tcell
vaccin
respiratori
virus
review
detail
elsewher
section
focu
import
memori
subset
cm
versu
em
frequenc
longev
memori
subset
rout
immun
substanti
clinic
evid
suggest
protect
tcell
immun
last
coupl
year
resolut
natur
infect
vaccin
unless
respons
boost
reexposur
crossreact
antigen
similarli
anim
model
influenza
sendai
viru
infect
efficaci
protect
secondari
challeng
wane
rapidli
within
month
primari
infect
declin
protect
tcell
immun
occur
despit
fact
number
virusspecif
memori
cell
lymphoid
tissu
cm
cell
remain
rel
high
life
span
anim
studi
suggest
context
respiratori
viral
infect
cm
cell
may
respond
expand
reloc
lung
suffici
quickli
provid
immedi
protect
diseas
caus
reinfect
livepathogen
challeng
postvaccin
recent
studi
indic
postinfect
total
number
virusspecif
em
cell
lung
substanti
higher
number
cm
cell
drain
ln
howev
detail
kinet
studi
reveal
despit
stabl
number
memori
cell
lymphoid
organ
number
lungand
airwayresid
memori
cell
follow
primari
sendai
viru
influenza
infect
gradual
declin
first
month
stabil
low
level
interestingli
declin
stabil
number
memori
cell
lung
directli
correl
progress
declin
cellmedi
protect
secondari
challeng
thu
develop
strategi
elicit
suffici
larg
number
longliv
em
cell
cytolyt
also
polyfunct
defin
abl
produc
high
level
antivir
cytokin
ifnc
tnf
repres
key
challeng
next
gener
vaccin
abl
confer
protect
respiratori
virus
regard
becom
increasingli
evid
strength
durat
antigen
stimul
play
import
role
determin
frequenc
longterm
persist
em
cell
discuss
despit
continu
disagr
precis
detail
memori
tcell
gener
occur
peopl
accept
amplitud
memori
tcell
pool
gener
viral
clearanc
dictat
magnitud
primari
effector
tcell
respons
phenomenon
well
studi
number
infecti
mous
model
includ
influenza
viru
five
tcell
elicit
peak
immun
respons
transit
memori
cell
primari
determin
effector
tcell
size
appear
function
initi
amount
antigen
present
tcell
prime
shown
brief
period
antigen
stimul
antigen
avail
prime
favor
enrich
cm
cell
wherea
prolong
period
support
em
cell
gener
fig
import
implic
vaccin
develop
respiratori
virus
exampl
level
time
antigen
exposur
provid
attenu
vaccin
nonrepl
vector
dna
vaccin
protein
subunit
vaccin
might
significantli
less
provid
liverepl
vaccin
like
link
capac
replic
vaccin
divid
multipl
time
dissemin
faster
thu
increas
amount
durat
antigen
exposur
discuss
detail
one
key
question
induc
larg
effectorcel
burst
size
new
vaccin
defin
precis
mechan
regul
format
effector
cell
context
high
persist
antigen
load
role
antigen
determin
longterm
persist
memori
cell
intens
debat
last
year
initi
data
mous
model
suggest
tcell
memori
short
live
absenc
period
exposur
antigen
howev
recent
evid
challeng
idea
suggest
number
cm
cell
sustain
absenc
specif
antigen
mhc
molecul
experiment
evid
suggest
cm
memori
pool
maintain
least
part
period
slow
cell
divis
continu
replac
cell
process
commonli
refer
homeostat
prolifer
turnov
memori
cm
pool
achiev
tonic
stimul
cytokin
contrast
em
cell
directli
maintain
homeostat
prolifer
two
differ
although
mutual
exclus
model
propos
explain
longev
em
cell
absenc
reexposur
antigen
initi
studi
suggest
em
cell
popul
lung
airway
maintain
antigenindepend
manner
continu
recruit
new
cell
circul
rate
memori
cell
recruit
shown
extrem
rapid
result
replac
popul
everi
day
maintain
period
year
follow
viral
clearanc
recent
studi
extend
observ
demonstr
antigen
persist
lung
drain
ln
sever
week
influenza
viru
clearanc
residu
antigen
contribut
mainten
em
cell
lung
airway
howev
small
number
circul
memori
tcell
gener
influenza
viru
infect
migrat
airway
absenc
cognat
antigen
therefor
memori
tcell
recruit
lung
airway
control
antigenindepend
antigendepend
mechan
immedi
follow
viru
clearanc
residu
antigen
clear
number
memori
tcell
local
within
lung
airway
stabil
low
level
antigenindepend
process
requir
maintain
popul
time
thu
clear
role
persist
antigen
vaccin
crucial
point
address
effect
tcell
vaccin
design
respiratori
virus
evid
clearli
demonstr
use
convent
nonrepl
attenu
vaccin
strain
fail
induc
robust
longliv
em
popul
therefor
limit
applic
design
futur
vaccin
explain
need
increas
vaccin
dose
number
booster
immun
highli
attenu
viral
vaccin
util
howev
approach
obviou
logist
econom
limit
thu
fulli
realiz
potenti
benefit
attenu
vaccin
simpl
protein
peptid
immun
great
interest
identifi
specif
molecul
pathway
target
safe
lower
activ
threshold
antigen
current
intraderm
intramuscular
oral
intranas
intravagin
even
rectal
rout
immun
activ
investig
accumul
evid
mani
research
group
confirm
rout
immun
critic
determin
qualit
quantit
aspect
vaccineinduc
immun
respons
regard
tcell
vaccin
respiratori
virus
recent
studi
support
concept
longliv
cell
detect
lung
mucos
system
immun
suggest
mainten
memori
cell
also
depend
particular
rout
vaccin
two
recent
studi
provid
insight
mechan
phenomenon
verbist
et
al
demonstr
gener
mainten
function
memori
cell
respiratori
influenza
infect
independ
surviv
signal
contrast
system
iv
induc
memori
cell
depend
longterm
surviv
thu
tcell
prime
mucos
site
requir
distinct
signal
longterm
mainten
shiki
takamura
et
al
extend
result
show
intranas
prime
memori
cell
possess
uniqu
abil
reactiv
residu
antigen
mln
compar
intraperiton
prime
cell
result
preferenti
recruit
mainten
intranas
prime
memori
cell
lung
airway
furthermor
demonstr
inabl
intraperiton
prime
memori
cell
access
residu
antigen
could
correct
subsequ
intranas
viru
infect
thu
initi
tcell
prime
mln
prolong
present
residu
antigen
mln
requir
maintain
larg
number
virusspecif
memori
cell
lung
airway
clearli
find
consid
ration
design
tcell
vaccin
respiratori
pathogen
poxvirusbas
vector
vaccinedeliveri
system
past
present
futur
sever
approach
use
elicit
protect
tcell
respons
includ
deliveri
protein
replicationcompet
attenu
recombin
virus
liveattenu
vaccin
replicationdefect
attenu
recombin
virus
dna
vaccin
protein
peptid
subunit
vaccin
combin
one
modal
heterolog
primeboost
strategi
current
two
extens
util
recombin
viral
vector
preclin
clinic
studi
deriv
poxvirus
adenovirus
detail
discuss
adenoviru
vector
dna
vaccin
protein
subunit
vaccin
provid
inform
reader
refer
follow
review
focu
remain
section
review
center
around
poxvirusbas
vector
list
tabl
specif
pursuit
safer
vaccin
paradox
result
larg
ineffect
tcell
vaccin
mucos
pathogen
poxvirus
famili
larg
envelop
virus
contain
linear
doublestrand
dna
genom
rang
size
kb
pair
cap
hairpin
loop
end
also
uniqu
encod
transcript
machineri
enabl
poxvirus
replic
cytoplasm
infect
cell
concept
util
liveattenu
poxvirus
immun
agent
respiratori
virus
trace
back
globalsmallpox
erad
program
strategi
program
involv
mass
vaccin
vacv
antigen
similar
viru
variola
major
etiolog
agent
smallpox
diseas
mani
liveattenu
vacv
strain
first
gener
vaccin
use
differ
part
world
lister
lister
elstre
strain
wide
use
vaccin
global
new
york
citi
board
health
nycboh
later
produc
wyeth
laboratori
dryvax
strain
use
america
west
africa
copenhagen
strain
denmark
ankara
strain
turkey
also
wide
use
vacv
variant
known
differ
express
sever
virul
factor
determin
replic
capac
safeti
profil
abil
vacv
strain
induc
robust
humor
cellmedi
immun
led
world
health
organ
declar
erad
smallpox
shortli
thereaft
routin
vaccin
vacv
could
discontinu
countri
serendipit
time
global
vacv
vaccin
program
termin
novel
molecular
biolog
tool
identifi
vacv
extrem
versatil
eukaryot
express
vector
one
main
properti
vacv
poxvirus
gener
provid
advantag
viral
vector
rel
eas
larg
insert
foreign
dna
clone
allow
insert
multipl
gene
creation
multival
vaccin
furthermor
poxvirus
potenti
administ
differ
rout
intraderm
intramuscular
oral
intranas
intravagin
intrarect
rout
gener
immunoglobulin
tcell
respons
last
year
grow
number
report
describ
util
recombin
vaccinia
virus
rvacv
express
relev
antigen
multipl
viral
bacteri
parasit
pathogen
confer
protect
immun
anim
vacv
strain
extens
util
anim
model
highli
virul
western
reserv
wr
strain
deriv
nycboh
strain
multipl
passag
mice
obviou
safeti
reason
wr
strain
repres
viabl
strain
use
human
vaccin
applic
moreov
welldocu
sever
albeit
rare
complic
follow
vaccin
first
gener
vacv
strain
increas
number
immunecompromis
individu
rais
legitim
concern
widespread
use
vaccinedeliveri
system
human
thu
past
three
decad
major
focu
research
develop
novel
highli
attenu
recombin
vacv
strain
rvacv
demonstr
significantli
improv
safeti
profil
use
human
potenti
vaccin
candid
tabl
briefli
mention
safeti
concern
surround
wr
first
gener
vacvbas
vaccin
candid
address
develop
highli
attenu
vacv
strain
tabl
includ
attenu
modifi
vaccinia
viru
ankara
mva
copenhagenderiv
nyvac
strain
mva
replic
defici
mammalian
cell
importantli
retain
capac
synthes
viral
protein
nyvac
highli
attenu
viru
unabl
produc
infecti
particl
human
viru
vector
extrem
safe
use
young
children
immunocompromis
individu
addit
attenu
avipoxvirusvaccin
vector
canari
pox
like
alvac
also
develop
use
human
due
restrict
tissu
tropism
avian
cell
alvac
safe
use
immun
compromis
human
recent
year
mva
nyvac
alvac
util
vari
degre
success
promis
vaccin
vector
mani
infecti
diseas
includ
influenza
sar
hiv
hsv
tb
malaria
furthermor
novel
vaccin
vector
increasingli
use
vari
degre
success
develop
therapeut
vaccin
sever
common
cancer
antigen
larg
number
clinic
trial
produc
complic
pictur
regard
use
vaccin
vector
gener
robust
tcell
respons
despit
small
number
clinic
trial
provid
promis
preliminari
evid
tcell
induct
unfortun
mani
trial
demonstr
limit
induct
antigenspecif
cell
infecti
diseas
cancer
target
interest
exampl
immunogen
attenu
alvac
vaccin
human
shown
low
elicit
tcell
respons
less
normal
volunt
similarli
immunogen
mva
express
gag
protein
consensu
clade
sever
immunodomin
tcell
epitop
also
shown
unsatisfactori
respons
smaller
studi
use
vaccin
higher
dose
show
enhanc
immunogen
respons
tcell
respons
induc
exclus
tcell
driven
regard
respiratori
virus
small
phase
clinic
trial
healthi
adult
investig
novel
mvabas
heterosubtyp
influenza
vaccin
mva
np
demonstr
volunt
signific
increas
number
ifnc
produc
cell
blood
week
one
three
eight
intraderm
intramuscular
vitro
stimul
assay
enhanc
cell
activ
prolifer
cytokin
product
restimul
respons
vitro
summari
agonist
vectorbas
adjuv
strategi
use
viral
non
viral
infecti
diseas
model
abbrevi
ip
intraperiton
iv
intraven
im
intramuscular
intranas
sc
subcutan
ifa
incomplet
freund
adjuv
ds
dermal
scarif
vacv
vaccinia
viru
vacvwr
vaccinia
viru
western
reserv
hbsag
hepat
b
surfac
antigen
siv
simian
immunodefici
viru
mcmv
murin
cytomegaloviru
hiv
human
immunodefici
viru
correspond
refer
studi
number
refer
vaccin
respons
howev
rapidli
declin
time
reach
prevaccin
level
week
postvaccin
consist
earlier
preclin
studi
demonstr
mvainduc
cell
respons
follow
sever
week
later
dramat
contract
phenomenon
also
occur
dnapoxviru
regimen
nyvac
alvac
use
boost
anoth
interest
characterist
mva
vaccin
reveal
pillai
et
al
mvaprim
gagspecif
memori
cell
found
predominantli
cm
phenotyp
posit
similarli
singl
immun
mva
vector
express
preerythrocyt
malaria
antigen
reyessandov
et
al
found
mvainduc
acceler
cm
rather
em
gener
consequ
fail
protect
malaria
studi
suggest
mva
current
form
may
effect
poxviru
vector
induct
strong
longlast
protect
tcell
respons
peripher
tissu
lung
one
look
back
literatur
becom
evid
somewhat
disappoint
clinic
result
nonrepl
highli
attenu
poxvirus
could
predict
base
studi
carri
ago
semin
studi
morgan
et
al
demonstr
virul
vacv
vector
critic
influenc
protect
efficaci
recombin
vaccin
cottontop
tamarin
vaccin
vacvwrbas
recombin
express
envelop
antigen
epsteinbarr
viru
ebv
protect
ebvinduc
lymphoma
anim
inocul
attenu
wyeth
vacvnycboh
base
recombin
precis
mechan
investig
detail
appear
independ
humor
immun
summari
year
increas
safeti
regulatori
concern
surround
replicationcompet
recombin
poxvirus
unfortun
result
widespread
use
vaccinedeliveri
vector
ineffect
induc
robust
longliv
memori
cell
necessari
confer
protect
highli
virul
respiratori
virus
dawn
recombin
poxvirusvaccin
research
rel
littl
known
precis
molecular
mechan
govern
quantiti
phenotyp
qualiti
memori
tcell
follow
infect
live
replic
viru
interim
gain
number
import
insight
must
consid
pursuit
safe
effect
poxvirusbas
tcell
vaccin
first
replicationcompet
highli
virul
poxvirus
gener
promot
potent
primari
memori
tcell
respons
compar
replicationdefect
highli
attenu
vaccin
strain
second
replicationdefect
poxvirus
predominantli
drive
induct
cm
cell
em
cell
third
mani
instanc
multipl
dose
higher
dose
pfu
replicationdefect
highli
attenu
poxvirusvaccin
strain
necessari
achiev
compar
level
cell
produc
live
poxvirusvaccin
strain
final
attenu
poxviru
strain
provid
good
short
term
tcell
protect
effect
confer
long
term
tcellmedi
protect
discuss
previous
limit
logic
relat
antigen
load
antigen
persist
abil
effect
stimul
tcell
respons
thu
convinc
argument
made
key
challeng
util
attenu
poxviru
vector
develop
efficaci
tcell
vaccin
defin
molecular
mechan
link
virul
immunogen
toward
end
sever
recent
studi
indic
key
event
initi
tcell
prime
includ
inflammatori
stimuli
costimul
tcell
help
cytokin
mileu
longlast
program
effect
quantiti
phenotyp
qualiti
memori
cell
gener
respons
live
viral
infect
follow
section
discuss
import
tcell
costimulatori
receptor
specif
focu
import
tnf
tnfr
famili
member
elicit
protect
tcell
memori
potenti
use
immunolog
adjuv
enhanc
poxvirusbas
tcell
vaccin
hypothes
coevolut
pathogen
host
major
drive
forc
behind
develop
highli
sophist
extrem
adapt
vertebr
immun
system
coevolut
clearli
demonstr
fact
mani
larg
dna
virus
poxvirus
herpesvirus
possess
multipl
homologu
cytokin
chemokin
associ
receptor
molecul
neutral
modul
host
immun
favor
viru
assum
main
goal
immun
modulatori
strategi
enhanc
viral
replic
surviv
howev
highli
plausibl
exist
unknown
consequ
viral
immun
evas
strategi
may
impact
host
immun
respons
could
possibl
certain
molecular
pathway
regul
altern
immun
respons
involv
autoimmun
allerg
even
antitumor
respons
might
evolv
differenti
util
consequ
viral
evas
tactic
obviou
exampl
larg
number
costimulatori
receptor
especi
immunoglobulin
ig
tnf
tnfr
superfamili
express
cell
known
critic
activ
icosicosl
typifi
costimulatori
molecul
ig
superfamili
wherea
tnfr
tnf
famili
member
typifi
exclus
gitrgitrl
hvemlight
member
tnf
tnfr
superfamili
recogn
abil
stimul
cell
provid
signal
promot
sustain
tcell
clonal
expans
longterm
surviv
achiev
select
target
intracellular
signal
molecul
promot
effector
cytokin
product
cell
divis
suppress
apoptosi
interestingli
number
receptorligand
pair
within
tnf
tnfr
superfamili
constitut
express
induc
specif
inflammatori
scenario
thought
provid
late
signal
subtli
regul
tcell
respons
quantit
qualit
manner
mani
costimulatori
molecul
exist
often
appar
similar
overlap
function
attribut
remain
determin
sever
pox
herp
virus
encod
tnfr
superfamili
homologu
tnfr
hvem
act
decoy
receptor
modul
host
immun
respons
favor
viral
replic
persist
interest
recent
analysi
teleost
genom
organ
first
fulli
function
adapt
immun
system
thought
develop
reveal
presenc
mani
human
tnf
superfamili
ortholog
provid
evid
suggest
mani
tnf
superfamili
member
coemerg
around
time
antigen
receptor
interestingli
howev
four
ligand
found
exist
within
teleost
genom
name
ligand
gitrl
briefli
discuss
import
regul
later
phase
tcell
expans
surviv
lead
hypothesi
ligand
may
arisen
recent
allow
immun
adapt
plastic
effect
develop
protect
immun
pathogen
test
hypothesi
recent
util
sever
poxviru
infect
model
investig
use
role
select
tnf
tnfr
ig
famili
member
initi
sustain
protect
tcell
respons
util
panel
vacv
strain
vari
degre
virul
mice
laboratori
recent
demonstr
rel
virul
viru
vaccin
dictat
quantiti
protect
capac
result
memori
tcell
gener
three
vacv
strain
use
studi
includ
highli
virul
wr
strain
two
clinic
relev
vacvvaccin
strain
lister
nycboh
vacv
strain
known
differ
express
sever
virul
factor
impact
replic
capac
vivo
consequ
found
intranas
intraperiton
infect
wr
vacv
strain
replic
rapidli
reach
high
titer
across
multipl
tissu
salekardakani
unpublish
observ
result
sever
sustain
inflamm
contrast
lister
nycboh
strain
clear
rapidli
unabl
dissemin
extent
wr
mice
infect
attenu
vacvvaccin
strain
lister
nycboh
via
intranas
intraperiton
rout
gener
five
fewer
lung
resid
virusspecif
memori
cell
compar
mice
infect
virul
replic
suffici
wr
strain
similar
differ
observ
peak
day
seven
eight
initi
effector
tcell
respons
impli
alter
molecular
regul
phase
respons
could
explain
differ
size
memori
pool
gener
highlight
import
cell
protect
subsequ
viral
encount
mhc
classiidefici
mice
mhc
ii
lack
cell
therefor
gener
vacvspecif
humor
immun
vaccin
wr
lister
nycboh
challeng
day
later
lethal
intranas
dose
vacvwr
mice
vaccin
wr
strain
virul
viru
surviv
lethal
infect
present
mild
diseas
symptom
contrast
protect
evid
mice
vaccin
either
attenu
strain
lister
nycboh
result
compar
mortal
diseas
sever
observ
unvaccin
mice
demonstr
vacv
strain
capabl
replic
greater
titer
multipl
tissu
longer
period
time
promot
greater
number
persist
antigenreact
cell
afford
protect
highli
lethal
respiratori
viru
challeng
human
immun
liveattenu
vacv
lister
nycboh
elicit
previous
thought
good
memori
tcell
respons
vacvspecif
memori
tcell
pool
shown
persist
mani
year
major
vaccin
recipi
howev
recent
observ
highlight
rapid
declin
memori
tcell
number
occur
signific
group
individu
time
rais
concern
whether
optim
longliv
tcell
immun
fact
gener
use
first
gener
vacv
strain
data
provid
consider
evid
warrant
concern
vaccin
use
virul
vacvwr
promot
far
superior
number
protect
memori
tcell
result
rais
question
whether
specif
molecular
mechan
exist
engag
infect
virul
wr
strain
attenu
lister
nycboh
vacv
strain
altern
molecular
control
mechan
evid
could
potenti
har
enhanc
tcell
respons
gener
attenu
poxviru
vaccin
member
tnfr
famili
constitut
express
cell
induc
hour
day
tcr
engag
maxim
express
typic
observ
two
five
day
follow
tcell
activ
downregul
impli
delay
mode
action
primari
immun
respons
consist
recent
report
seen
proport
vacvspecif
cell
earli
day
four
peak
day
five
postinfect
vacvwr
initi
studi
found
develop
high
number
effector
cell
capabl
produc
ifnc
tnfa
strongli
impair
lack
tcell
respond
vacv
analysi
main
immunodomin
tcell
popul
account
close
whole
vacvspecif
respons
demonstr
global
impair
tcell
prime
absenc
respons
reduc
demonstr
engag
activ
virul
viral
infect
ensur
gener
high
frequenc
persist
function
memori
cell
locat
lung
interestingli
driven
induct
lungresid
memori
cell
correl
directli
robust
protect
highli
lethal
intranas
infect
vvwr
subsequ
assess
requir
infect
lister
nycboh
vacv
strain
strike
contrast
vacvwr
littl
differ
frequenc
virusspecif
effector
memori
cell
observ
absenc
signal
thu
virul
host
evas
mechan
vacvwr
result
persist
viral
replic
engag
costimulatori
receptor
subsequ
result
enhanc
induct
memori
cell
afford
protect
highli
lethal
respiratori
viru
challeng
light
studi
postul
whether
differenti
engag
appli
tcell
stimulatori
receptor
regard
recent
data
group
other
shown
addit
costimulatori
receptor
ig
superfamili
anoth
tnfr
famili
member
util
vacvwr
infect
contribut
gener
effector
tcell
respons
distinguish
constitut
present
rest
cell
respect
ligand
similar
induc
apc
receiv
certain
inflammatori
stimuli
contrast
studi
found
indispens
optim
effector
tcell
gener
regardless
whether
mice
infect
lister
nycboh
howev
similar
defici
result
impair
tcell
respons
wr
littl
defect
lister
nycboh
anoth
interest
distinct
infect
virul
wr
attenu
virus
evid
vacvspecif
tcell
respons
assess
memori
phase
mice
exhibit
defect
memori
tcell
gener
respons
lister
nycboh
interestingli
wr
even
though
requir
optim
effector
respons
viru
indic
respons
vacvwr
infect
exist
phase
tcell
prime
follow
phase
signal
previous
shown
prolong
tcell
surviv
beyond
effector
phase
immun
respons
thu
serv
increas
number
memori
cell
inhibit
effector
tcell
death
consist
result
block
interact
mice
late
primari
respons
five
eight
day
complet
abrog
tcell
respons
vacvwr
result
support
model
tempor
sequenc
event
necessari
optim
virusspecif
tcell
prolifer
surviv
memori
gener
brought
specif
sequenti
engag
costimulatori
molecul
summari
show
viral
virul
evas
strategi
impact
viral
replic
dissemin
invari
inflammatori
milieu
lead
differenti
use
costimulatori
receptor
cell
dictat
magnitud
effect
tcell
respons
fig
furthermor
data
high
potenti
signific
vaccin
promot
notion
use
attenu
virus
may
elicit
best
longterm
tcell
memori
allow
molecul
ligand
may
evolv
purpos
promot
tcell
memori
engag
provid
hypothet
model
might
part
explain
abund
stimulatori
receptor
cell
demonstr
molecular
plastic
occur
antivir
respons
certain
immun
mechan
thought
nonessenti
could
becom
highli
relev
contrari
vacvwr
studi
similar
data
vacvlist
vacvnycboh
discuss
regul
tcell
respons
viral
set
variabl
depend
signal
initi
studi
mice
independ
infect
lymphocyt
choriomening
viru
lcmv
vesicular
stomat
viru
vsv
theiler
murin
encephalomyel
tmev
influenza
viru
demonstr
defect
control
viral
replic
gener
effector
tcell
popul
howev
recent
studi
investig
impact
signal
memori
recal
tcell
respons
demonstr
reduct
number
secondari
expans
memori
cell
lung
despit
influenc
initi
tcell
prime
similarli
signal
regul
accumul
cell
reactiv
persistentphas
epitop
mous
cytomegaloviru
mcmv
infect
collect
data
suggest
two
virus
initi
combin
costimulatori
pathway
rais
mani
question
surround
specif
signal
initi
program
costimulatori
pathway
requir
induct
mainten
recal
memori
tcell
popul
discuss
level
viru
replic
persist
brought
virul
immun
evas
strategi
one
paramet
dictat
differenti
use
costimulatori
receptor
subsequ
magnitud
efficaci
ensu
tcell
respons
furthermor
inflammatori
signatur
initi
specif
viru
strain
presenc
virusspecif
virul
factor
may
also
author
particular
costimulatori
interact
apc
deriv
vacvwr
level
viru
replic
brought
virul
immun
evas
tactic
lead
differenti
use
cell
stimulatori
receptor
tnfr
ig
superfamili
dictat
magnitud
tcell
respons
two
tnfr
famili
member
drive
gener
memori
cell
viru
replic
strongli
higher
dose
attenu
viru
use
inocul
contrast
interact
interact
use
gener
memori
respons
attenu
virus
rapidli
clear
correspond
strongli
reduc
tcell
memori
differenti
molecular
use
alter
tcell
memori
determin
abil
host
protect
subsequ
respiratori
infect
cytokin
tnfa
shown
influenc
extent
length
costimulatori
receptor
ligand
express
recent
lcmv
studi
reveal
differenti
requir
type
ifn
control
initi
expans
gener
cell
use
respons
vacv
infect
furthermor
engag
tlr
ligat
deriv
signal
also
regul
express
apc
summari
extent
viral
replic
term
peak
titer
tissu
tropism
uniqu
inflammatori
signatur
specif
viral
infect
like
influenc
use
specif
combin
costimulatori
molecul
studi
investig
spatial
tempor
express
profil
costimulatori
ligand
receptor
differ
viral
set
almost
certainli
add
understand
help
develop
safe
yet
effect
vaccin
viral
infect
accumul
evid
laboratori
other
support
notion
critic
compon
futur
tcell
vaccin
highli
virul
respiratori
virus
must
capac
promot
robust
expans
precursor
cell
reactiv
viral
antigen
peptid
ii
allow
high
frequenc
virusspecif
effector
cell
surviv
time
memori
cell
iii
allow
high
number
memori
cell
persist
lung
parenchyma
airway
absenc
persist
antigen
iv
retain
high
effector
function
provid
optim
surveil
subsequ
infect
allud
earlier
replicationdefect
highli
attenu
poxviru
vector
although
extrem
safe
unlik
satisfi
number
import
requir
consequ
number
innov
strategi
develop
facilit
enhanc
immunogen
attenu
poxviru
vector
includ
use
heterolog
primeboost
regiment
coadministr
tlr
agonist
cytokin
target
tcell
costimulatori
receptor
studi
highlight
suggest
attenu
vacvvaccin
strain
elicit
effect
tcell
memori
respons
lung
due
lack
engag
therefor
investig
whether
engag
would
boost
respons
attenu
vacvvaccin
strain
treat
agonist
antibodi
agonist
treatment
initi
prime
tcell
markedli
enhanc
number
effector
memori
cell
spleen
also
lung
observ
regardless
whether
vaccin
via
intraperiton
dermal
scarif
rout
significantli
agonist
provid
strong
protect
lethal
respiratori
viru
challeng
mhc
ii
mice
vaccin
lister
nycboh
alon
ineffect
prevent
lethal
extent
protect
mice
vaccin
combin
attenu
vaccin
strain
agonist
similar
mice
vaccin
virul
wr
strain
extend
result
focus
prime
cell
subcutan
immun
immunodomin
vacv
peptid
epitop
given
ifa
strategi
allow
us
assess
role
memori
cell
absenc
preexist
vacvspecif
immunoglobulin
presenc
intact
tcell
popul
sever
week
later
memori
cell
develop
mice
challeng
intranas
lethal
dose
vacvwr
correl
prior
data
agonist
provid
strong
protect
depend
independ
manner
mice
vaccin
high
dose
peptid
diseas
measur
weight
loss
observ
stress
prevent
weight
loss
first
seven
day
infect
extrem
difficult
achiev
especi
highchalleng
dose
x
ld
use
experi
therefor
import
demonstr
util
agonist
target
antivir
protect
interestingli
target
induc
almost
complet
protect
mice
immun
low
dose
alon
ineffect
prevent
lethal
reflect
minim
loss
weight
mortal
well
lung
immunopatholog
extent
protect
directli
correl
number
ifnc
produc
memori
tcell
gener
lung
engag
number
accumul
intranas
infect
find
reminisc
obtain
secondari
influenza
sendai
viru
infect
presenc
signific
number
cell
lung
challeng
correl
immun
develop
polyfunct
cell
consid
potent
memori
cell
antivir
immun
power
metric
potenc
adjuvant
agonist
treatment
time
vaccin
elicit
highli
polyfunct
cell
persist
specif
lung
tissu
high
number
least
secondari
challeng
vacv
importantli
independ
tcell
help
previous
discuss
effect
promot
lung
tropic
memori
cell
rout
vaccin
virul
immunogen
vaccin
vector
paramount
collect
studi
demonstr
intraperiton
infect
attenu
vacvvaccin
strain
subcutan
vaccin
viral
peptid
presenc
agonist
antibodi
gener
longlast
memori
cell
persist
lung
therefor
target
prime
vacvspecif
cell
elicit
fulli
protect
longliv
antivir
tcell
respons
lung
irrespect
site
vaccin
context
viral
antigen
sever
group
rais
possibl
trigger
could
enhanc
vaccin
efficaci
viral
nonvir
pathogen
use
poxvir
vector
encod
antigen
interest
combin
demonstr
enhanc
splenic
tcell
respons
hepat
b
surfac
antigen
hbsag
improv
protect
efficaci
footandmouth
diseas
fmd
vaccin
furthermor
recombin
poxviru
vector
encod
combin
enhanc
tcell
prolif
capac
cytokin
product
antigen
restimul
vitro
similar
approach
canari
pox
vaccin
vector
coadminist
intramuscularli
canarypox
vector
result
expans
hivspecif
cell
detect
spleen
sixweek
postinfect
use
agonist
antibodi
fusion
protein
also
produc
promis
result
coadministr
agonist
antibodi
rhesu
monkey
result
enhanc
virusspecif
cell
immunoglobulin
recal
respons
target
use
agonist
monoclon
antibodi
elicit
strong
antivir
cell
mcmv
infect
result
enhanc
clearanc
viru
furthermor
stimul
cooper
vaccin
ovaexpress
poxviru
vector
also
enhanc
ovaspecif
memori
respons
approach
also
promot
fungal
clearanc
enhanc
tcell
respons
respiratori
fungal
pathogen
cryptococcu
neoforman
summari
agonist
vectorbas
adjuv
strategi
shown
tabl
collect
studi
suggest
promis
target
enhanc
tcell
respons
varieti
antigen
agonist
reagent
encod
within
vaccin
vector
might
use
vaccin
regimen
strategi
could
enabl
highli
desir
abil
retain
use
attenu
vaccin
simpl
peptid
protein
immun
promot
immunoglobulin
tcell
compon
immun
respons
comprehens
insight
molecular
mechan
agonist
therapi
review
without
doubt
greatest
concern
enhanc
tcell
respons
use
agonist
antibodi
vector
encod
hyperinflammatori
immun
respons
clinic
trial
investig
propens
induc
regulatori
cell
develop
use
superagonist
antibodi
result
six
human
volunt
experienc
lifethreaten
complic
consequ
futur
clinic
trial
target
tcell
stimulatori
receptor
undoubtedli
face
stringent
safeti
requir
regulatori
author
end
toxic
trial
nonhuman
primat
alreadi
demonstr
agonist
antibodi
therapi
well
toler
safe
therefor
provid
strong
rational
pursu
clinic
test
human
direct
interact
viral
pathogen
also
rais
concern
surround
target
enhanc
tcell
respons
recent
identifi
cell
entri
receptor
felin
fiv
hiv
replic
subsequ
kill
express
cell
fiv
hiv
would
preferenti
deplet
virusspecif
cell
would
otherwis
mediat
antivir
immun
respons
tcell
tropic
virus
may
also
exploit
axi
aid
dissemin
exampl
infect
human
tcell
leukemia
viru
type
caus
agent
adult
tcell
leukemia
atl
enhanc
express
cooper
process
involv
nfjb
viral
oncoprotein
tax
intriguingli
small
number
atl
patient
display
depend
adhes
leukem
cell
endotheli
cell
suggest
virusinduc
express
could
enhanc
leukem
cell
infiltr
viral
dissemin
virus
hijack
transcript
activ
event
trigger
induc
express
gene
number
virus
includ
cytomegaloviru
hiv
nfjb
respons
element
incorpor
genom
enhanc
viral
reactiv
case
cmv
viral
replic
possibl
influenc
viral
replic
surviv
reactiv
latenc
repres
interest
area
futur
research
final
research
potenti
pathogen
enhanc
tcell
respons
upon
natur
viru
reexposur
necessari
inappropri
memori
tcell
respons
upon
reexposur
rsv
vaccin
formalininactiv
vaccin
result
sever
infant
death
countless
hospit
consequ
would
necessari
determin
safe
upper
limit
number
memori
tcell
desir
also
whether
maintain
larg
number
tissu
resid
lung
memori
cell
detriment
time
summari
although
promis
target
enhanc
protect
infect
reduc
viralinduc
immunopatholog
posit
effect
may
viru
replic
surviv
infect
host
cell
rais
new
consider
manipul
make
infecti
statu
patient
paramount
import
accumul
evid
indic
target
human
hold
great
promis
futur
vaccin
strategi
highli
virul
respiratori
virus
unmet
clinic
infecti
diseas
hiv
malaria
tb
literatur
discuss
provid
compel
evid
suggest
target
costimulatori
pathway
similar
molecul
famili
promot
robust
expans
antigenspecif
effector
cell
respons
safe
attenu
vacvvaccin
strain
peptid
antigen
furthermor
stimul
gener
longliv
memori
effector
cell
capabl
surviv
mucos
site
absenc
persist
antigen
maintain
effector
function
provid
protect
natur
reexposur
doubt
increas
understand
basic
tcell
biolog
dynam
regulatori
influenc
mani
costimulatori
pathway
gener
phenotyp
mainten
reactiv
cell
facilit
develop
novel
tcell
vaccin
key
area
research
provid
import
insight
plastic
adapt
costimulatori
regul
tcell
respons
identifi
differ
inflammatori
signatur
virus
elicit
potent
tcell
respons
enabl
us
recapitul
signatur
virul
viru
use
safe
attenu
vaccin
viru
promot
lifelong
cellmedi
immun
